44th week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090269332 | Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 2009-10-29 |
20090269333 | REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS - Peptides of influenza virus hemagglutinin protein and | 2009-10-29 |
20090269334 | BIOMARKERS FOR GRAFT REJECTION - Methods are disclosed for diagnosing rejection in a transplanted subject, monitoring rejection in a transplanted subject at risk thereof, preventing, inhibiting, reducing or treating rejection in a transplanted subject, or identifying agents for use in the prevention, inhibition, reduction or treatment of rejection, based on genes which are differentially expressed in transplanted subjects. | 2009-10-29 |
20090269335 | THERAPEUTIC AGENT FOR PROSTATE CANCER - The present inventors investigated the antitumor effects of anti-IL-6 receptor antibodies against prostate cancer. The result showed that the anti-IL-6 receptor antibodies had both in vivo and in vitro antitumor effects against prostate cancer. It was also revealed that the hPM1 antitumor effect is via IL-6 receptor. | 2009-10-29 |
20090269336 | ANTI-VEGF MONOCLONAL ANTIBODY - The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF. | 2009-10-29 |
20090269337 | COMPOSITIONS AND METHODS FOR TREATING DIABETES - Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided. | 2009-10-29 |
20090269338 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 2009-10-29 |
20090269339 | RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY - The present invention provides clinical data evaluating the efficacy of responses to immunizations in rheumatoid arthritis (RA) patients treated with a CD20 antibody. | 2009-10-29 |
20090269340 | ANTIBODIES TO ONCOSTATIN M RECEPTOR - The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta. | 2009-10-29 |
20090269341 | LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME - The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies. | 2009-10-29 |
20090269342 | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto - The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto. | 2009-10-29 |
20090269343 | Dual Specific Immunotoxin for Brain Tumor Therapy - We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors. | 2009-10-29 |
20090269344 | Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues - The invention relates to an indidualized and personalized diagnosis and therapy of cancer based on specific molecular alterations which occur in specific tumor tissue of specific tumor patient populations. The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues are unaffected by the same anti-EGFR antibody treatment. | 2009-10-29 |
20090269345 | CLN248 Antibody Compositions and Methods of Use - Isolated anti-Cln248 antibodies that bind to Cln248 and cells that produce the anti-Cln248 antibodies are provided. Also provided are compositions of an anti-Cln248 antibody and a carrier. In addition, isolated nucleic acids encoding an anti-Cln248 antibody, as well as an expression vector for the isolated nucleic acids are provided. Methods for identifying anti-Cln248 antibodies, methods for producing the anti-Cln248 antibodies, as well as methods for their use in killing a Cln248-expressing cancer cells and alleviating or treating a Cln248-expressing cancer in a mammal are also provided. | 2009-10-29 |
20090269346 | Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof - The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins. | 2009-10-29 |
20090269347 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2009-10-29 |
20090269348 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2009-10-29 |
20090269349 | ANTIGENIC POLYPEPTIDES - The invention relates to a method for the identification of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes; vaccines comprising said antigens; and therapeutic antibodies directed to said antigenic polypeptides. | 2009-10-29 |
20090269350 | Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC1C, NARC 1A, NARC 25, 86604 and 32222 molecules and uses therefor - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2009-10-29 |
20090269351 | METHOD OF DIAGNOSING AND TREATING GLIOMA - The present invention is directed to methods and compositions for the diagnosis, prognosis and treatment of glioma in mammals. | 2009-10-29 |
20090269352 | ANTITUMOR AGENT COMPRISING SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND COMBINED WITH AN ANGIOGENESIS INHIBITOR - The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor. | 2009-10-29 |
20090269353 | Stimulation of T Cells Against Self-Antigens Using CTLA-4 Blocking Agents - Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation. | 2009-10-29 |
20090269354 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT - This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases. | 2009-10-29 |
20090269355 | Catalytic antibodies and a method of producing same - The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes. | 2009-10-29 |
20090269356 | Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders - Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer. | 2009-10-29 |
20090269357 | ANTI-TNFalpha ANTIBODY - An antibody that binds TNF α and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2. | 2009-10-29 |
20090269358 | Proteins with Improved Solubility and Methods for Producing and Using Same - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 2009-10-29 |
20090269359 | Method of Treatment and Prophylaxis of Diseases Related to Amyloid Deposition Using IGM - The invention relates to a method of treating or preventing disease associated with β-amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations. | 2009-10-29 |
20090269360 | THERAPY - The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent. | 2009-10-29 |
20090269361 | Constructs for delivery of therapeutic agents to neuronal cells - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 2009-10-29 |
20090269362 | Method for Controlling Immunodominance - Methods for controlling immunodominance are described. These methods are carried out by altering the kinetic stability of a complex between a class II Major Histocompatibility Complex (MHC) molecule and the epitope for which immunodominance is to be altered. Alterations that increase the kinetic stability of the epitope: class II MHC complex confer immunodominance upon the epitope. Methods are also described for stimulating an immune response in an organism to a specific epitope by administering to the organism a form of that epitope which has been altered to be immunodominant. | 2009-10-29 |
20090269363 | METHOD FOR SCREENING PEPTIDES FOR USE IN IMMUNOTHERAPY - Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa). | 2009-10-29 |
20090269364 | HER-2/NEU MULTI-PEPTIDE VACCINE - The present invention relates to a multi-peptide-multiepitop-vaccine against cancerous diseases associated with HER-2/neu oncogene, i.e. the vaccine comprises a specific combination of peptides presenting different amino acids sequences as occur in the extracellular domain of HER-2/neu protein. | 2009-10-29 |
20090269365 | IMMUNOGENIC VACCINIA PEPTIDES AND METHODS OF USING SAME - The invention provides specific proteins encoded by the vaccinia genome that elicit an immune memory response and can be used for vaccines directed against variola (smallpox), monkeypox and other poxviruses. The invention provides antigens, polypeptides comprising antigens, polynucleotides encoding the polypeptides, vectors, and recombinant viruses containing the polynucleotides, antigen-presenting cells (APCs) presenting the polypeptides, immune cells directed against the epitopes, and pharmaceutical compositions. The invention additionally provides methods, including methods for preventing and treating infection, for killing infected cells, for inhibiting viral replication, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, and for enhancing production of disease-specific antibody. | 2009-10-29 |
20090269366 | T CELL EPITOPE PEPTIDES OF 6B11 OVARIAN CANCER ANTI-IDIOTYPIC ANTIBODY - The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer. | 2009-10-29 |
20090269367 | METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN COUNT CYCLES - The present invention provides methods of predicting increases in pathogenic virulence, morbidity, and/or mortality or expansion in pathogen populations within regions or into new regions by identifying cycles or ratios of increasing concentrations of a family of small peptides expressed in pathogens and provides compounds comprising the small peptides for treatment and prevention of pathogenic outbreaks. | 2009-10-29 |
20090269368 | PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS - This invention provides | 2009-10-29 |
20090269369 | Ophthalmic Composition Comprising Xanthan Gum and Glucose - The present invention provides an ophthalmic composition containing xanthan gum and glucose, which has a superior corneal epithelial disorder-treating effect. | 2009-10-29 |
20090269370 | VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS - The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided. | 2009-10-29 |
20090269371 | Process for the production of monoclonal antibodies - Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof. | 2009-10-29 |
20090269372 | Enhanced Antiviral Activity Against Foot and Mouth Disease - Previously, we showed that type I interferon (alpha/beta interferon [IFN-α/β]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 10 | 2009-10-29 |
20090269373 | Saposin C-DOPS: A Novel Anti-Tumor Agent - Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor. | 2009-10-29 |
20090269374 | COSMETIC COMPOSITIONS FOR IMPROVING THE PERFORMANCE OF TRANSFER-RESISTANT AND LONG-WEARING - The present invention provides a cosmetic composition including oil phase ingredients 40-90% by weight and powder ingredients 10-60% by weight. The oil phase ingredients include volatile oil 5-70 parts by weight and dimethicone/vinyl-dimethicone crosspolymer 0.1-5 parts by weight. The powder ingredients include organic hectorite 0.5-40 parts by weight, methyl methacrylate crosspolymer 0.5-5 parts by weight, and pulverulent body 0.5-50 parts by weight. | 2009-10-29 |
20090269375 | Tanning compositions containing juice concentrate - A topical tanning composition comprises an aqueous continuous phase comprising water; and at least one fruit or vegetable juice; at least one optional compound selected from the group consisting of tanning accelerators, bronzers, and a mixture thereof; and a non-aqueous discontinuous phase. The composition is made by mixing water and a fruit or vegetable juice to make an aqueous juice phase; preparing a nonaqueous mixture of at least one thickener; at least one hydrophobic solvent, wax or oil; and an emulsifier to make a hydrophobic phase; mixing the hydrophobic phase and the aqueous juice phase to form a uniform emulsion; and optionally adding at least one component selected from the group consisting of tanning accelerators, bronzers, and a mixture thereof to the uniform emulsion. | 2009-10-29 |
20090269376 | Stabilization of cosmetic compositions - A composition of matter is used as an ingredient in cosmetics comprising at least 0.5% by weight and preferably 1-30% by weight of highly refined cellulose fiber in a cosmetic composition. Additionally present in the composition are other conventional cosmetic ingredients as known in the art. This composition may include at least colorants (dyes and pigments), lipophilic materials, aqueous materials (water and aqueous solutions), waxes, binding agents (polymers, thickening agents), emollients, emulsifiers, thickening agents, antioxidants, natural and synthetic oils and extracts, clays, ultraviolet radiation absorbers, and the like. | 2009-10-29 |
20090269377 | COSMETIC COMPOSITION FOR CARE AND/OR TREATMENT AND/OR MAKEUP OF THE EMULSION TYPE STRUCTURED WITH SILICONE POLYMERS - Cosmetic emulsion for care and/or makeup, comprising an aqueous phase and a liquid fatty phase dispersed one within the other, said liquid fatty phase comprising at least one silicone oil and being structured with at least one gelling polymer (homopolymer or copolymer) with a weight-average molecular mass ranging from 500 to 500,000, containing at least one moiety comprising:
| 2009-10-29 |
20090269378 | USE OF TANNINS IN FILTERS - The present invention relates to the use of a tanning agent in or on filters, in particular natural or synthetic fibrous fabric or foams, for the avoidance of infections, these filters in particular being part of respiratory protection masks or respiratory protection apparatuses. | 2009-10-29 |
20090269379 | Material Having Antibacterial and Antifungal Properties - A garment or footwear based on a synthetic thermoplastic polymer material containing (a) an antibacterial agent selected from phenolic antimicrobial compounds of the formula (I) wherein n is 0 or preferably 1, R | 2009-10-29 |
20090269380 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS - The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition. | 2009-10-29 |
20090269381 | Pest Control Agent - Disclosed are a pest control composition, a method of pest control, and a method for preparing a pest control composition. The pest control composition includes diatomaceous earth, a porous granular starch, and a control agent, the control agent generally being an oleaginous material that is film-forming on a water surface. The pest control composition generally is in the form of discrete plural compacted particles. Upon release, for instance, onto a body of water, the control agent will be released from the pest control composition and will form a film over at least a portion of the body of water. | 2009-10-29 |
20090269382 | FORMULATION - A product comprising microcapsules which themselves comprise (a) a polymeric shell; and (b) a core comprising an agrochemical which has a melting point greater than or equal to 25° C. characterised in that the agrochemical is dispersed as a solid in a hydrophobic material which has a melting point greater than or equal to 25° C. but which does not exhibit a glass transition temperature. | 2009-10-29 |
20090269383 | MEDICAL DEVICES HAVING INORGANIC PARTICLE LAYERS - An expandable medical device having a particle layer disposed over a reservoir containing a therapeutic agent. The particle layer has a first porosity when the medical device is in the unexpanded configuration and a second porosity when the medical device is in the expanded configuration. The particle layer comprises a plurality of micron-sized or nano-sized particles. In certain embodiments, the particles are not connected to each other, and as such, the different porosities are provided by changes in the spacing between the particles as the medical device is expanded/unexpanded. Also disclosed are medical devices having a particle layer, wherein the particle layer comprises a plurality of encapsulated particles, and methods of coating medical devices with particles. | 2009-10-29 |
20090269384 | BIOACTIVE THERMOGELLING POLYMER SYSTEMS AND METHODS OF THEIR USE - Hydrogels comprising poly(N-alkylacrylamide), poly(alkyleneglyco)di-acrylate or methacrylate, cross-linking agent, a source of calcium ions, and water are described, as well as methods of their preparation and use. | 2009-10-29 |
20090269385 | COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells. | 2009-10-29 |
20090269386 | COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells. | 2009-10-29 |
20090269387 | COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells. | 2009-10-29 |
20090269388 | ALLOGRAFT BONE COMPOSITION HAVING A GELATIN BINDER - The invention is directed toward an osteoimplant for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing composition of demineralized allograft bone material mixed with an aqueous phosphate buffered gelatin which when lyophilized to remove water from the composition crosslinks the gelatin to form a solid structure and when rehydrated is flexible | 2009-10-29 |
20090269389 | ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery - ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic. | 2009-10-29 |
20090269390 | MEDICAL DEVICES, POLYMERS, COMPOSITIONS, AND METHODS FOR DELIVERING A HALOACETATE - Polymers, compositions, and medical devices useful for delivering (e.g., by local and/or sustained delivery) a haloacetate (e.g., dichoroacetate) to a tissue are disclosed herein. Such methods can be useful for treatment of diseases such as cancer. | 2009-10-29 |
20090269391 | Drug Delivery System And Methods Of Use - Electrospun fibers are utilized to improve the mechanical characteristics of a contact lens reducing the weight and mechanical strength of the polymers from which the lenses are typically formed. Electrospun fibers are also utilized as a drug delivery system, both through direct use in the eye and by inclusion of the fibers in a contact lens. The fibers are loaded with therapeutic drugs by a variety of methods and processed by coating and cross-linking the fibers. | 2009-10-29 |
20090269392 | Drug Delivery System And Methods Of Use - Electrospun fibers are utilized to improve the mechanical characteristics of a contact lens reducing the weight and mechanical strength of the polymers from which the lenses are typically formed. Electrospun fibers are also utilized as a drug delivery system, both through direct use in the eye and by inclusion of the fibers in a contact lens. The fibers are loaded with therapeutic drugs by a variety of methods and processed by coating and cross-linking the fibers. | 2009-10-29 |
20090269393 | Chewable Bilayer Tablet Formulation - Disclosed herein is a tablet formulation of an objectionable tasting drug cetirizine or its pharmaceutically acceptable salt in a form of chewable bilayer tablet, wherein the formulation comprises said cetirizine, a combination of water-insoluble and water-soluble polymer in a ratio of about 1:0.5 to about 1:5 and a low molecular weight polyol, wherein the molar ratio of the low molecular weight polyol to cetirizine is more than 10, and the inactive formulation layer comprises beta-cyclodextrin and other pharmaceutically acceptable excipients. Further, the present invention provides a process for preparing the formulation. | 2009-10-29 |
20090269394 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS - The present invention relates to methods for treating and completely curing fungal, yeast and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition. | 2009-10-29 |
20090269395 | USE OF PROTOBERBERINES AS AN ACTIVE SUBSTANCE REGULATING THE PILOSEBACEOUS UNIT - The present invention relates to cosmetic use, by topic application on the skin of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an active substance reducing activity of the pilosebaceous unit, preferably inhibiting activity of the pilosebaceous unit. In particular, the invention relates to cosmetic use of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an agent reducing, preferably inhibiting the growth of hairs of the face and/or the body, and/or seborrheic activity of the sebaceous glands. The invention also relates to a cosmetic composition comprising in a dermatologically acceptable carrier, at least one protoberberine, with exception of berberine, or a vegetable extract containing protoberberines, as an active substance, which reduces, preferably inhibits the skin's pilosebaceous unit activity. | 2009-10-29 |
20090269396 | DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described. | 2009-10-29 |
20090269397 | TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS - Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other fields. Targeted polymeric microparticles have also been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered. | 2009-10-29 |
20090269398 | Compositions for the encapsulation of natural product extracts in oil medium in hard gelatin capsules and a method of encapsulation - The present invention relates to compositions of natural extracts in oil medium, prepared in non-free-flowing formulations, and encapsuled in hard gelatin capsules, without post-fill sealing. These compositions comprise a therapeutically effective amount of at least one natural extract in oil medium, the composition suitable for treating a medical condition, and at least one oil-absorbent ingredient in powder form. More specifically, the natural extract in the composition can be an extract of | 2009-10-29 |
20090269399 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts. | 2009-10-29 |
20090269400 | Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin - The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix. | 2009-10-29 |
20090269401 | Controlled Release Solid Preparation - Disclosed is a solid preparation which comprises at least one active ingredient and at least one dissolution-controlling base substance and can be formed by compression molding, wherein the dissolution-controlling base substance contains 5.0 to 99.9% by weight (inclusive) of a modified starch having a moisture retaining capacity of 400% or more and a gel indentation load of 200 g or more, containing a water-soluble ingredient in an amount of 40 to 95% by weight, having particles passing through a 75 μm-mesh sieve in the proportion of 90% by weight or more and particles passing through a 32 μm-mesh sieve in the proportion of 20% by weight or more, and having an average particle diameter of not smaller than 20 μm and smaller than 50 μm. | 2009-10-29 |
20090269402 | MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine. | 2009-10-29 |
20090269403 | ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of drugs for use as a female oral contraceptive. In an embodiment, an oral dosage form includes a progestogen dispersed in an enteric polymer and an estrogen. | 2009-10-29 |
20090269404 | Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods - A multi-layer crosslinked gelatin gel structure having a layer structure that plural layers of crosslinked gelatin gel crosslinked by irradiating gelatin or a gelatin derivative with electron beam under an oxygen-containing atmosphere are arranged adjoiningly to each other, a preparation for release of a bioactive factor with the bioactive factor contained in the multi-layer crosslinked gelatin gel structure, and production processes thereof. | 2009-10-29 |
20090269405 | ENZYME MEDIATED DELIVERY SYSTEM - The present invention includes compositions, methods, and systems for the development of a novel delivery vehicle that affects release of an agent upon the degradation of components of said vehicle by one or more enzymes. In one example, the system comprises components designed to degrade upon the presence of desired concentrations of proteinases, specifically matrix metalloproteinases, and subsequent release of the agent. | 2009-10-29 |
20090269406 | Therapeutic uses of biocompatible biogel compositions - The present invention relates to biocompatible biogel compositions and methods of drug delivery. The biocompatible biogel is a physical polymer matrix formed via affinity interactions between its components. The components of the biocompatible biogel comprise a cationic component, an anionic component, and optionally a therapeutic agent. | 2009-10-29 |
20090269407 | Poly-alpha(1-4)glucopyranose-based matrices with hydrazide crosslinking - The present invention provides biocompatible, biodegradable matrices formed from poly-α(1→4)glucopyranose and reactive hydrazide groups. The matrices can be used for various applications in the body, including drug delivery and cell therapy. | 2009-10-29 |
20090269408 | Aqueous formulations of imidoalkanepercarboxylic acids - Liquid formulations of imidoalkanepercarboxylic acids, in the form of aqueous dispersions comprising, in percentages by weight relative to the total weight of the composition: A) from ≧7% to 40% and preferably from 10% to 20% of imidoalka-nepercarhoxylic acids having the general formula (I), the said imidoalkanepercarboxylic acids being in the β form and having a dissolution time, determined via the test of the rate of dissolution at a temperature of 40° C. or 18° C., of not more than 5 minutes when determined at 40° C. or 15 minutes when determined at 18° C., for an amount of dissolved acid equal to 99% of the theoretical amount; B) from 0.001% to 0.9% of a nonionic surfactant; the said dispersions having a viscosity of not more than 2000 mPa·sec at 25° C. by applying a shear rate of 20 s | 2009-10-29 |
20090269409 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESZOPICLONE - Pharmaceutical compositions comprising eszopiclone, including its pharmaceutically acceptable salts, hydrates, clathrates, solvates, polymorphs, and mixtures thereof. The invention also relates to processes for preparing the compositions and their methods of use. | 2009-10-29 |
20090269410 | Inhibition of Neovascularization by Cerium Oxide Nanoparticles - The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject. | 2009-10-29 |
20090269411 | MASKING THE TASTE OF POWDERS - Taste-masked powders that can be inhaled or administered orally, a simple method for the production thereof, and the use thereof for applying biologically active substances. | 2009-10-29 |
20090269412 | Pharmaceutical formulations for dry powder inhalers - A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device. | 2009-10-29 |
20090269413 | FLOWABLE COLLAGEN MATERIAL FOR DURAL CLOSURE - Flowable graft materials are provided which comprise collagen powder and a liquid in an amount sufficient to impart a flowable consistency to the material. The graft materials are sufficiently formable and pliable so as to provide both superior contact with and easier access to a surgical site than typical, more rigid grafts such as collagen sheets. These flowable materials may also be in a fluidized, paste-like and/or gel-like state and may be moldable and/or ejectable. The flowable collagen materials reduce and/or eliminate post implantation problems associated with other materials, e.g. synthetic dural sealants (hemostasis products), such as product swelling after application and implantation. The flowable graft materials are particularly useful as a dural graft. | 2009-10-29 |
20090269414 | PROCESS OF PREPARING MICROSPHERES FOR SUSTAINED RELEASE HAVING IMPROVED DISPERSIBILITY AND SYRINGEABILITY - Disclosed is a process of preparing sustained release microspheres, containing a biodegradable polymer as a carrier and a drug, using spray drying. The process comprises preparing a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent; spray drying the solution, suspension or emulsion; and suspending spray-dried microspheres in an aqueous solution containing polyvinyl alcohol to remove the residual solvent and increase the hydrophilicity of the microsphere surface. The process enables the preparation of microspheres having high drug encapsulation efficiency, almost not having a toxicity problem due to the residual solvent, and having good syringeability. The microspheres prepared according to the present invention release an effective concentration of a drug in a sustained manner for a predetermined period when administered to the body, and are thus useful in the treatment of diseases. | 2009-10-29 |
20090269415 | NOVEL THERAPEUTIC AGENT DERIVED FROM MARINE ORGANISM - There is provided a nerve repairing agent, anti-ulcer agent or the like comprising an extract from a marine organism selected from organisms belonging to the class Holothuroidea, the phylum Porifera and the order Actiniaria or a material removed from a viscus of the organism. The extract has the following properties (1) to (4): (1) it is a almost colorless, transparent and viscous liquid having a slight fishy smell, or a almost white powder having a slight fishy smell which, when dissolved in water, is almost colorless and viscous; (2) a solution prepared by dissolving the liquid or powder in water shows the maximum absorbance at a wavelength of 264±10 nm; (3) a solution prepared by dissolving the liquid or powder in water shows an acidic pH value; and (4) it has at least one effect selected from a cranial nerve repairing effect, a nerve-growing effect, an insulin-releasing effect, an immunopotentiating effect, a noxious pain preventive effect, a neurogenic pain preventive effect, a diabetic sensory neuropathy ameliorating effect and an ulcer preventive effect. | 2009-10-29 |
20090269416 | Compositions and Methods For Preventing or Treating Chronic Renal Failure in Felines With Hyperthyroidism - The invention relates to compositions for preventing chronic renal failure (CRF) in felines with hyperthyroidism wherein the compositions comprise (1) from about 28 to about 35% protein, the protein comprising at least about 75% vegetable protein, and (2) from about 0.1 to less than about 1 mg/kg iodine and/or from about 0.1 to about 1 mg/kg selenium. The invention also relates to compositions for treating CRF in hyperthyroid felines wherein the compositions comprise (1) from about 28 to about 35% protein, the protein comprising at least about 75% vegetable protein, and (2) from about 0.1 to less than about 0.3 mg/kg iodine and/or from about 0.1 to about 1 mg/kg selenium. The invention further relates to methods for preparing and using such compositions, articles of manufacture comprising such compositions, and means for communicating information about such compositions, methods, and articles of manufacture. | 2009-10-29 |
20090269417 | THIOLATED CHITOSAN GEL - Bodily tissue and structures may be coated with a protective gel layer made from a two-part composition whose first part contains thiolated chitosan and whose second part contains sufficient oxidizing agent or external crosslinking agent so that when the two parts are mixed and coated onto the tissue or structure the mixture will form a protective gel layer in less than 30 minutes. | 2009-10-29 |
20090269418 | Compositions and Methods for Inducing Hair Growth - Novel therapeutic methods and pharmaceutical compositions utilizing tellurium-containing compounds for inducing hair growth for the treatment of various types of alopecia and other conditions associated with hair loss. | 2009-10-29 |
20090269419 | COSMETIC COMPOSITION BASED ON POLYUNSATURATED FATTY ACIDS AND ITS USES - The present invention relates to a cosmetic or dermatological composition comprising (i) at least vegetables oils which are rich in omega-3 and/or in omega-6, selected from the group consisting of echium oil, cameline oil, evening primrose oil and borage oil, the vegetable oils being present in a proportion such as to provide an omega-3 to omega-6 ratio within said composition of between 1 and 5, (ii) at least one mineral, preferably in salt form, selected from the group consisting of sodium, calcium and magnesium, preferably magnesium, (iii) at least one trace element selected from the group consisting of zinc, copper and iron, preferably from the group consisting of zinc and copper, (iv) at least vitamin C or derivative thereof, and (v) at least one essential oil, which has anti-free-radical properties, for performing a deep-down treatment which stimulates the microcirculation and the production of energy for the purpose of imparting dynamism to the cells and accelerating their renewal, protecting the collagen, and combating pigmentation spots. | 2009-10-29 |
20090269420 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE - The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing. | 2009-10-29 |
20090269421 | COATING MATERIAL - It is an object of the present invention to provide a coating material for a biomedical material surface which can control cell adhesiveness/non-cell adhesiveness and improve the biocompatibility of a material surface. The present invention provides a coating material for a surface of a biomedical material, which comprises a recombinant gelatin. | 2009-10-29 |
20090269422 | METHODS FOR CONTROLLING ANGIOGENESIS AND CELL PROLIFERATION - The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins. | 2009-10-29 |
20090269423 | Foot-bath Agent of Chinese Herbal Medicine for Regulating Blood pressure and Improving Sleep Quality - The present invention relates to a foot-bath agent of Chinese herbal medicine for regulating blood pressure and improving sleep quality, and the components of the formula thereof are as follows: fructus leonuri 20-25%, semen ziziphi spinosae 15-20%, calcined magnetitum 17-22%, spica prunellae 15-20%, ligusticum chuanxiong hort 18-23%, borneolum 0.7-1.2%; provided that, after the final product is prepared using the above raw materials and the blending ratios thereof, the sum of all components should be 100% by weight. The foot-bath agent prepared has advantages including an efficacious and healthy method thereof being highly consistent with healthy living habits of people, an effective regulation of blood pressure and improvement of sleep quality, no allergy and less side effects to human body, and thus obviously is worthy to be popularized and has market prospect. | 2009-10-29 |
20090269424 | Peripheral blood flow-improving composition - The present invention provides a composition that can effectively improve peripheral blood flow to thereby ameliorate cold sensation, numbness, pains and other skin symptoms, as well as frostbites, chilblains and chaps and other skin disorders associated with disturbed peripheral blood flow. This composition has no side effects. Specifically, the peripheral blood flow-improving composition contains, as an active ingredient, a extract of a plant of the genus | 2009-10-29 |
20090269425 | Formulation and method for relieving or preventing symptoms associated with uric acid crystals - A method for relieving or preventing symptoms associated with uric acid crystals, comprising consuming a formulation that supports three or more processes, the processes comprising:
| 2009-10-29 |
20090269427 | HERBAL COMPOSITION FOR INFLAMMATORY DISORDERS - This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, | 2009-10-29 |
20090269428 | UNDERWATER PELLETIZER - An underwater pelletizer for cutting extruded plastic into a flow of liquid is disclosed. The pelletizer includes a cutter hub ( | 2009-10-29 |
20090269429 | SUPERFINE FIBER CREATING SPINNERET AND USES THEREOF - Apparatuses and methods for the production of superfine fibers. | 2009-10-29 |
20090269430 | INJECTION MOLDING APPARATUS HAVING EDGE-GATED RUNNERLESS NOZZLE AND RELATED METHOD OF TIP REMOVAL - A nozzle body defines an upstream channel. A downstream bracing portion has a lateral bore. A nozzle tip extends laterally through the lateral bore of the bracing portion and has a sealing surface for engaging a gate component that defines a mold gate. The runnerless nozzle further includes a securing component inserted into the bracing portion to hold the nozzle tip against the bracing portion. The bracing portion or the securing component defines a lateral channel in communication with the upstream channel for delivering molding material to the nozzle tip. The nozzle tip can be removed by removing the securing component. | 2009-10-29 |
20090269431 | Compression molding an annular closure shell - Apparatus for compression molding an annular closure shell having a base wall with a center opening and, in accordance with one aspect of the disclosure, includes male and female mold sections having associated male and female mold surfaces that generally oppose each other. The female mold section includes an opening in the female mold surface and a mold pin extending through the opening. The male and female mold surfaces cooperate to generally define the base wall of the annular closure shell and the mold pin cooperates with the male mold section to generally define the center opening of the annular closure shell. Closure of the male and female mold sections forms an annular mold cavity for receiving and compression molding a mold charge into the annular closure shell having the base wall with the center opening, which at least partially surrounds the mold pin. | 2009-10-29 |
20090269432 | RECEIVING JIG - To separate resin molded parts that are used for a push button switch member with less light leakage from the side faces and less trouble in key operation, easily, a resin molded body comprises one or more resin molded parts for a push button switch member, a frame surrounding the outside of the resin molded parts, one or more gates connecting a plurality of the resin molded parts each other or the resin molded part to the frame and one or more runners crossing the longitudinal direction of the gates, wherein the gates are connected at the back faces of the resin molded parts not to be coated with light shielding paint, and wherein the runners are connected to the gates on the same surfaces as the resin molded parts are connected to and are connecting the opposing sides of the frame. | 2009-10-29 |